Prof. Christian Marth, MD, PhD [7505]

In what kind of tumors have studies confirmed improved survival using molecular marker-targeted therapy? (German) Video

In what kind of tumors have studies confirmed improved survival using molecular marker-targeted therapy? (German)

In what kind of tumors have studies confirmed improved survival using molecular marker-targeted therapy? (German)
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD

In what ways is NGS-based genomic profiling changing our fundamental approaches to cancer treatment? (German) Video

In what ways is NGS-based genomic profiling changing our fundamental approaches to cancer treatment? (German)

In what ways is NGS-based genomic profiling changing our fundamental approaches to cancer treatment? (German)
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD

Why is comprehensive characterization of genomic alterations that defines an individual patient’s tumor useful for oncologists and pathologists to guide optimal therapeutic strategies? (German) Video

Why is comprehensive characterization of genomic alterations that defines an individual patient’s tumor useful for oncologists and pathologists to guide optimal therapeutic strategies? (German)

Why is comprehensive characterization of genomic alterations that defines an individual patient’s tumor useful for oncologists and pathologists to guide optimal therapeutic strategies? (German)
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD

What percentage of HER2 amplifications are not detectable by current tests? (German) Video

What percentage of HER2 amplifications are not detectable by current tests? (German)

What percentage of HER2 amplifications are not detectable by current tests? (German)
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD

Can targeted therapies based on NGS-based genomic alterations be employed after a patient has failed first-line therapy? Are targeted therapies late in a disease as successful as at time of presentation? (German) Video

Can targeted therapies based on NGS-based genomic alterations be employed after a patient has failed first-line therapy? Are targeted therapies late in a disease as successful as at time of presentation? (German)

Can targeted therapies based on NGS?based genomic alterations still be employed even after a patient has failed a first?line therapy? Are targeted therapies late in the natural history of a patient’s disease as successful as using mutation?based ...
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD

Is there a rationale for longitudinal NGS-based testing for genomic alterations? (German) Video

Is there a rationale for longitudinal NGS-based testing for genomic alterations? (German)

Is there a rationale for longitudinal NGS-based testing for genomic alterations? (German)
Prof. Christian Marth, MD, PhD

Prof. Christian Marth, MD, PhD